10 Non-COVID News Updates To Listen For In Second Quarter Reporting
Executive Summary
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.
You may also be interested in...
Merck Warned Of Q2 Slump, But How Far Did Revenue Fall?
The company previously cut 2020 revenue expectations by $2.5bn, including $1.7bn for pharma products. Keytruda’s dominance and portfolio diversification also may dominate second quarter call.
Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies
US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.
Biogen/Eisai Hit ‘Send’ On High Stakes BLA For Aducanumab In Alzheimer’s Disease
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.